Over one million Australian adults have obstructive sleep apnoea (OSA). Untreated OSA has major adverse health, social and economic consequences. There are multiple causes of OSA. Less than 50% of OSA patients tolerate the first-line therapy, continuous positive airway pressure (CPAP). Second-line therapies (e.g. upper airway surgery and dental devices) have variable and unpredictable efficacy. Thus, new treatments are urgently required. This project will use advanced respiratory phenotyping techniques pioneered by the research team at NeuRA/UNSW combined with standard clinical sleep assessments to develop new tailored therapies including combination therapy for people with OSA.
Back to search results